国家统计局：2026年1月份中国制造业采购经理指数为49.3% 比上月下降0.8个百分点 国家统计局、中国物流与采购联合会31日发布2026年1月份中国采购经理指数。数据显示，1 月我国制造业市场需求有所收紧，但企业生产保持扩张态势，产业结构继续优化；服务业运行 态势相对稳定，企业预期持续向好。2026年1月份中国制造业采购经理指数为49.3%，比上月 下降0.8个百分点。1月份装备制造业采购经理指数为50.1%，高技术制造业采购经理指数为 52%，装备制造业和高技术制造业稳中向好发展，制造业产业结构持续优化。 北京经济技术开发区：推进数模混合、存算一体等芯片架构研发创新 延伸场景定义芯片、行 业专用芯片、使能软件等产业链条 北京经济技术开发区管理委员会印发《关于进一步加快建设全域人工智能之城的实施方案 （2026—2027年）》。其中提到，夯实智能原生基础能力。发挥集成电路制造能力优势，推 动"设计-制造-封测-算力"一体化协同发展，牵引算力基础设施与高性能智算产业持续迭代。推 进数模混合、存算一体等芯片架构研发创新，延伸场景定义芯片、行业专用芯片、使能软件等 产业链条。推动通用与垂类模型协同发展，加快认知 ...

Core Viewpoint - The strategic collaboration between CSPC Pharmaceutical Group and AstraZeneca, valued at up to $18.5 billion, was met with unexpected market skepticism, leading to a significant drop in stock prices for both companies involved [2][4][7]. Group 1: Strategic Collaboration Details - CSPC Pharmaceutical Group announced a strategic partnership with AstraZeneca to co-develop innovative long-acting peptide drugs based on CSPC's drug delivery technology and AI discovery platform [3][4]. - The agreement includes a $1.2 billion upfront payment, up to $3.5 billion in research milestone payments, and $13.8 billion in sales milestone payments, along with a double-digit revenue share based on annual net sales [4][5]. - This deal surpasses the previous record of $11.4 billion set by Innovent Biologics and Takeda in 2025, marking a new high for outbound licensing in China's biopharmaceutical sector [4]. Group 2: Market Reaction and Concerns - Following the announcement, CSPC's stock fell by 9.82% to HKD 9.64 per share, while its closely related company, New Horizon Health, saw a drop of 15.72% [2][7]. - Analysts suggest that the market's negative reaction stems from concerns over the details of the deal and the companies' fundamentals, indicating that the perceived benefits may not align with the actual risks involved [7]. - The milestone payments are contingent on successful clinical trials and market performance, raising questions about the viability of CSPC's projects in a competitive landscape [7][8]. Group 3: Product and Competitive Landscape - The core asset in this collaboration is SYH2082, a long-acting weight management drug currently in Phase I clinical trials, targeting GLP-1R and GIPR receptors [8][9]. - The competitive landscape for GLP-1 drugs is intensifying, with major players like Eli Lilly and domestic companies rapidly advancing their own dual-target and multi-target drugs [9][10]. - CSPC's late entry into the clinical phase with SYH2082 presents challenges in efficacy differentiation and safety optimization, which will be critical for its future competitiveness [10]. Group 4: Financial Context and Implications - CSPC's decision to pursue this significant licensing deal comes at a time when its financial performance is under pressure, with a reported revenue decline of 12.32% year-on-year for the first three quarters of 2025 [11]. - New Horizon Health stands to benefit from the upfront payment, which will help alleviate its cash flow issues as it anticipates a significant net loss in 2025 due to high R&D expenditures [12].

Core Insights - The innovative drug Enoglutide Injection (brand name Xianyida) developed by Hangzhou Xianweida Biotechnology Co., Ltd. has received approval from the National Medical Products Administration, marking a significant milestone for the company and the industry [1] - This drug is aimed at blood sugar control for adult patients with type 2 diabetes and is the first approved innovative drug in Zhejiang Province for 2026, providing a new treatment option for over 100 million diabetes patients globally [1] Company Overview - Xianweida was established in August 2017 and has focused on innovative weight management therapies for obesity and related diseases [1] - Enoglutide is the company's first approved product and represents a breakthrough as the world's first biased GLP-1 (glucagon-like peptide-1) hypoglycemic drug [1] - The biased GLP-1 developed by Xianweida offers a significant upgrade over traditional GLP-1 receptor agonists, achieving better clinical efficacy while maintaining blood sugar control [1] Product Pipeline and Market Position - In addition to type 2 diabetes, Xianweida is targeting indications for overweight/obesity with multiple products in the pipeline, including a submitted application for Enoglutide for obesity in China [2] - The company is developing several oral products and aims to become the "first stock in weight management" by submitting a prospectus to the Hong Kong Stock Exchange in September 2025 [2] - The GLP-1 sector is currently one of the hottest areas in the global biopharmaceutical field, attracting major pharmaceutical companies like Novo Nordisk, Eli Lilly, Pfizer, and AstraZeneca, as well as numerous innovative biotech firms in China [2] Industry Context - The successful approval of the new drug is seen as a significant milestone for Chinese pharmaceutical companies in the field of metabolic diseases [2] - Hangzhou has been promoting rapid development in the biopharmaceutical industry through policy support and ecosystem optimization, with 5 innovative drugs approved in 2025, accounting for 83% of the total in the province [2] - The Hangzhou Medical Port has seen 132 innovative drugs enter clinical trials, with 4 currently in the approval process [2]

1月30日，新诺威（300765）及其间接控股股东石药集团相继公告，宣布与全球生物制药巨头阿斯利康 (AstraZeneca)签署战略研发合作与授权协议，将在创新多肽分子发现和长效递送产品的开发领域开展全 面战略合作。 合作总金额 最高可达185亿美元 根据石药集团公告，在中国以外，阿斯利康将获得该集团"每月一次注射用体重管理产品组合"的全球独 家权利——包括一个临床准备就绪的项目SYH2082(长效GLP1R/GIPR激动剂，正推进至I期临床)，以及 三个处于临床前阶段、具备不同作用机制的研发项目。 根据石药集团公告，阿斯利康将向石药集团支付12亿美元预付款。此外，石药集团有权获得最高35亿美 元的潜在研发里程碑付款和最高138亿美元的潜在销售里程碑付款，以及基于相关授权产品年净销售额 的最高达双位数比例的销售提成。若所有里程碑均达成，该合作总金额最高可达185亿美元。 针对此次合作，添翼数字经济智库高级研究员吴婉莹对记者表示，此次石药集团与阿斯利康创纪录的战 略合作，标志着其"创新+国际化"战略取得里程碑式突破，不仅以巨额合作金额强力验证了其AI药物发 现与缓释给药等前沿技术平台的全球竞争力，为正处于传统 ...

Core Viewpoint - The strategic collaboration between CSPC Pharmaceutical Group and AstraZeneca aims to develop innovative long-acting peptide drugs, leveraging CSPC's proprietary drug delivery technology and AI discovery platform, with a potential total value of up to $18.5 billion [2][5][6]. Group 1: Collaboration Details - CSPC has signed a strategic R&D collaboration and licensing agreement with AstraZeneca, which includes a $1.2 billion upfront payment and potential milestone payments of up to $3.5 billion for R&D and $13.8 billion for sales [2][5]. - AstraZeneca will gain exclusive global rights (excluding mainland China, Hong Kong, Macau, and Taiwan) to develop, manufacture, and commercialize a weight management product portfolio, including the clinical-ready project SYH2082 [5][6]. - The collaboration will also focus on developing four additional projects based on CSPC's technology platforms [5]. Group 2: Market Potential - The global obesity issue is projected to escalate, with over 2.9 billion adults expected to be classified as having a high BMI by 2030, driving demand for GLP-1 receptor agonists [6][7]. - The GLP-1RA market is anticipated to reach a valuation of $100 billion by 2030, attracting significant interest from pharmaceutical companies [7][8]. - Existing GLP-1 drugs have shown substantial revenue growth, with Eli Lilly's drug generating $24.837 billion in revenue in the first three quarters of 2025, accounting for 54% of its total revenue [6][7]. Group 3: Competitive Landscape - The GLP-1 market is transitioning from an early "blue ocean" phase to a competitive landscape dominated by major players like Novo Nordisk and Eli Lilly, with ongoing opportunities for differentiation and innovation [7][8]. - Current trends in GLP-1 drug development are focusing on multi-target approaches, longer efficacy, and more convenient administration methods, with oral formulations becoming a key competitive focus [7][8]. Group 4: Financial Context - CSPC's recent collaborations are part of a broader trend in the biopharmaceutical sector, where partnerships are increasingly seen as a means to enhance cash flow and support ongoing R&D efforts [11][12]. - Despite recent collaborations, CSPC has faced financial pressures, with a reported revenue decline of 12.32% year-on-year for the first three quarters of 2025 [12].

Policy Developments - The National Healthcare Security Administration and the National Administration of Traditional Chinese Medicine announced the inclusion of Beijing and other regions in a pilot program for disease-based payment for traditional Chinese medicine [2] Drug and Device Approvals - Heng Rui Medicine received acceptance for a new indication application for its innovative drug, injection of Carrelizumab combined with Apatinib, for the treatment of unresectable hepatocellular carcinoma [4] - Lifesun Pharmaceutical announced that its Aminophylline tablets passed the consistency evaluation for generic drugs, which is expected to enhance market competitiveness [5] - Eli Lilly's Metabolically Associated Fatty Liver Disease indication for Tirzepatide has been included in the list of breakthrough therapies by the National Medical Products Administration [6] Financial Reports - Yiming Pharmaceutical projected a net profit increase of 61.12% to 122.08% for 2025, driven by the growth of its core product, Miglitol tablets [8] - Innovation Medical forecasted a net loss of 26 million to 33 million yuan for 2025, primarily due to tax expenses and adjustments in healthcare policies [9] Capital Markets - Kangchen Pharmaceutical upgraded its share repurchase plan to a total of 300 million Hong Kong dollars, extending the buyback period until the next annual general meeting [11] Industry Developments - Huawei Cloud is set to launch a smart healthcare section as part of its AI "Dream Factory" initiative, aiming to integrate top medical resources and advanced technology [14] - AstraZeneca announced plans to invest 15 billion USD in China by 2030 to expand research and production capabilities [16]

Market Overview - Microsoft shares dropped nearly 10%, significantly impacting the software sector and contributing to a decline in major U.S. stock indices, although the Dow Jones managed to close slightly up by 0.11% [1][2][4] - The S&P 500 index fell by 0.13% to 6969.01 points, while the Nasdaq Composite index decreased by 0.72% to 23685.12 points, with both indices experiencing larger intraday declines of 1.5% and 2.6% respectively [1][2] Company Performance - Microsoft reported a slowdown in cloud business growth from 40% to 39%, with a gross margin of approximately 68%, marking a three-year low. This led to a 9.99% drop in its stock price [4] - Other software companies such as ServiceNow, Salesforce, Oracle, and SAP also experienced declines in their stock prices, with drops of 9.94%, 6.09%, 2.19%, and 15.2% respectively [4] - The iShares Expanded Tech-Software Sector ETF (IGV) fell by 4.94%, entering a technical bear market with a 22% decline from recent highs [4] Technology Sector Insights - Rob Williams, Chief Investment Strategist at Sage Advisory, noted that while artificial intelligence (AI) has driven economic growth, it has also raised valuation concerns in the stock market. He emphasized the need for tech giants to report "explosive" earnings to boost market sentiment [6] - Meta Platforms saw a stock increase of 10.4% after announcing continued investment in AI, while Apple reported better-than-expected quarterly revenue, leading to a post-market stock rise of over 3% [6] Notable Stock Movements - Major tech stocks showed mixed performance: Nvidia rose by 0.52%, Alphabet (Google) increased by 0.71%, while Amazon, Broadcom, and Tesla saw declines of 0.53%, 0.75%, and 3.23% respectively [7][8] - The Philadelphia Semiconductor Index rose by 0.16%, reaching a new historical high, with notable gains from companies like Lam Research and KLA Corporation [7] Earnings Reports - Apple reported first-quarter revenue of $143.76 billion, a 16% year-over-year increase, exceeding expectations of $138.4 billion. iPhone revenue was $85.27 billion, up 23% from the previous year [10] - SanDisk's second-quarter revenue was $3.03 billion, surpassing the expected $2.67 billion, while Western Digital also reported better-than-expected earnings [11][12]

智通财经1月30日讯（编辑 赵昊）周四（1月29日），微软暴跌拖累美股早盘走低，但三大指数盘中持续缩小跌幅，最终道指收盘转涨。 截至收盘，标普500指数跌0.13%，报6969.01点；纳斯达克综合指数跌0.72%，报23685.12点。盘中，两只指数分别一度跌1.5%和2.6%。 | 名称 | | 最新价 | 涨跌额 | 涨跌幅 | | --- | --- | --- | --- | --- | | 道琼斯指数 | 0 | 49071.56 | +55.96 | 0.11% | | 标普500指数 | | 6969.01 | -9.02 | -0.13% | | 纳斯达克综合指数 | | 23685.12 | -172.33 | -0.72% | 道琼斯指数涨0.11%，报49071.56点，盘中一度跌0.85%。30只成分股中，22家上涨8家下跌，IBM、霍尼韦尔涨近5%，弥补了微软跌约10%的拖累。 前一交易日，微软发布的业绩报告显示，公司云业务增速从40%放缓至39%；毛利率约为68%，降至三年来最低。微软周四收跌9.99%，盘中一度跌逾12%。 微软的暴跌重创软件板块，季度盈利和营收均好于预期的Se ...

智通财经APP获悉，GIP（葡萄糖依赖性促胰岛素多肽）与GLP-1（胰高血糖素样肽-1）同属肠促胰岛素 家族，其受体GIPR在人体代谢调节中发挥着多维度的核心作用：在脂肪组织中促进脂质摄取与储存； 在骨骼中调节骨形成与转换；并在中枢神经系统（CNS）中参与食欲调节。近日，英矽智能宣布发现创 新GIPR拮抗剂ISM0676，该候选分子在临床前小鼠模型中实现用药27天减重31%的强大疗效，为评估 GIPR通路在减重治疗中的作用提供了新的临床前数据。 据披露，ISM0676由英矽智能(03696)借助其Pharma.AI人工智能药物发现平台赋能设计，从立项到临床 前候选化合物提名耗时14个月，累计合成测试不超过200个分子，体现了其以AI辅助提升早期研发效率 的探索路径。那么，GIPR拮抗剂是否会成为行业竞相追逐的下一款"神药"？ 人工智能在机制探索与分 子优化等环节，又将发挥多大作用？ GLP-1困局：减重数据的B面 此前，英矽智能创始人兼CEO Alex Zhavoronkov博士表示，代谢疾病领域（Cardiometabolics）有望成为 全球首个实现大批量健康寿命延长的突破口。学术界也有相关理论依据：例如 ...

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [3] Core Insights - The recent policy released by the Ministry of Commerce and eight other departments aims to promote high-quality development in the pharmaceutical retail industry, which is expected to accelerate industry consolidation and benefit leading companies [6][28] - The pharmaceutical retail sector is anticipated to see improved performance expectations due to favorable policies, with a recommendation to focus on quality pharmacy enterprises such as Yifeng Pharmacy and Dazhenglin [6][33] Market Performance - The pharmaceutical and biotechnology index decreased by 0.39% this week, outperforming the CSI 300 index by 0.23 percentage points, ranking 27th in industry performance [11] - Year-to-date, the pharmaceutical and biotechnology index has increased by 6.66%, outperforming the CSI 300 index by 5.1 percentage points, ranking 16th [11] - The best-performing sub-sector this week was pharmaceutical commerce, which rose by 4.26%, while chemical pharmaceuticals fell by 1.11% [17] Stock Performance - Among 478 pharmaceutical and biotechnology stocks, 338 stocks increased, representing 70.71% of the total [22] - The top five A-share stocks by performance this week were: *ST Changyao (+70.37%), Hualan Biological Engineering (+32.21%), Kangzhong Medical (+25.47%), Hanshang Group (+20.06%), and Wanze Shares (+19.04%) [22] - In the Hong Kong market, 116 pharmaceutical and biotechnology stocks saw 32 stocks rise, accounting for 27.59% [25] Industry News and Policies - The Ministry of Commerce and other departments released an opinion on promoting high-quality development in the pharmaceutical retail industry, proposing 18 specific measures to enhance service quality and optimize industry structure [28] - The FDA granted fast-track designation to CM336, a dual antibody developed by Kangnuo, for the treatment of autoimmune hemolytic anemia and immune thrombocytopenia [31] Recommendations - The report suggests focusing on quality pharmacy enterprises in light of the favorable policies for the pharmaceutical retail sector [33] - It also highlights the potential for vaccine companies in response to the recent Nipah virus cases in India, recommending attention to companies like Zhifei Biological, Kangtai Biological, Watson Bio, and CanSino [34]